ClinicalTrials.gg
Active, not recruitingNCT05070858NIMBLEUpdated Oct 28, 2026

A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

A Phase 3 interventional study of Pozelimab + Cemdisiran and Cemdisiran in Generalized Myasthenia Gravis, sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 116 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

Updated Oct 28, 2026Eligibility revised1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
288
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 144 studies in Myasthenia Gravis with a site in United States — 53 open to participants now, 73 under way, 25 of them phase 3. Myasthenia Gravis · United States.

Enrollment
Largest of 108
288 · median 56
Started
2021
with 12 others
Phase 3
45 of 144
9 open now
Primary completion
2025-07
later than 7 of 72 live
Registered
68th of 144
by date

Among the 144 studies in Myasthenia Gravis with a site in United States, this one has the largest enrollment of the 108 interventional ones that give a count, is one of 13 that started in 2021, is one of 45 in phase 3, reaches primary completion later than 7 of the 72 other live ones, and was the 68th registered.

Myasthenia Gravis

330 studies on the registry are indexed under Myasthenia Gravis; 144 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

53 of the 144 studies in Myasthenia Gravis with a site in United States are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 144 studies in Myasthenia Gravis with a site in United States, or all of them as a file.
02

Study summary

This study is researching the experimental drugs called pozelimab and cemdisiran, and cemdisiran monotherapy. The study is focused on patients with generalized Myasthenia Gravis (gMG). Myasthenia gravis is a disease that causes weakness and fatigue in muscles in the body because the nerves and muscles are not communicating properly.

The aim of the study is to see how effective pozelimab and cemdisiran are when used in combination and when pozelimab and cemdisiran are used alone for patients with gMG.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drugs
  • How the study drugs work inside the body
  • How much of the study drugs are in the blood at different times
  • Whether the body makes antibodies against pozelimab and cemdisiran (which could make the drugs less effective or could lead to side effects)
Read the detailed description

DBTP- Double Blind Treatment Period (24 weeks) ETP - Extension Treatment Period (28 weeks) OLTP- Open Label Treatment Period (68 weeks) FUP-Off treatment Follow Up Period (52 weeks)

03

Conditions studied

  • Generalized Myasthenia Gravis

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 28, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Male or female participants ≥18 years of age at screening (or ≥ legal age of adulthood based on local regulations, whichever is older)
  2. Participant with documented diagnosis of Myasthenia Gravis (MG) based on medical history and supported by previous evaluations as described in the protocol
  3. Documented prior history of positive serologic test or a positive result during screening of Anti-acetylcholine Receptor (AChR) antibodies or anti-Lipoprotein Receptor-related Protein 4 (LRP4) antibodies
  4. Myasthenia Gravis Foundation of America (MGFA) Clinical Classification Class II to IVa at screening
  5. Myasthenia Gravis-Activities of Daily Living (MG-ADL) score ≥6 at screening. Ocular items should not contribute more than 50% of MG-ADL total score as described in the protocol
  6. Currently receiving an acetylcholinesterase inhibitor or documented reason for not using acetylcholinesterase inhibitor therapy per investigator
  7. Currently receiving an Therapy (IST) for MG, or documented reason why the participant is not taking an IST per investigator
  8. If currently receiving an IST, not anticipated to have IST dosage changed before randomization or during Double-Blind Treatment Period (DBTP)
  9. Willing and able to comply with clinic visits and study-related procedures, including completion of the primary series of the meningococcal vaccinations required per protocol
  10. For the optional PK sub-study: Must have a (BMI) ≥ 18.5 kg/m\^2 and ≤ 30 kg/m\^2 at screening

Key Exclusion Criteria:

  1. Participants with antibody profile that is only positive for Muscle-Specific tyrosine Kinase (MuSK) (MuSK positivity is based on a documented prior history of positive serologic test for antibodies to MuSK or a positive result during screening
  2. History of thymectomy within 12 months prior to screening or planned during the study
  3. History of malignant thymoma (patients with stage 1 may be enrolled), or history of cancer within the past 5 years, except for adequately treated basal cell skin cancer, squamous cell skin cancer, or in situ cervical cancer
  4. Myasthenic crisis or MGFA Class V within 1 month of screening
  5. Not meeting meningococcal vaccination requirements and, at a minimum, documentation of quadrivalent meningococcal vaccination within 5 years prior to randomization and serotype B vaccine (when available) within 3 years prior to randomization as described in the protocol
  6. Known to meningococcal vaccines (group ACWY conjugate and group B vaccines) as described in the protocol
  7. Participants who require antibiotics for meningococcal prophylaxis and have a contraindication, warning, or precaution precluding the use of penicillin class and penicillin-alternative antibiotics planned to be used for prophylaxis, or a history of intolerance leading to the discontinuation of these antibiotics
  8. Positive surface antigen or virus Ribonucleic Acid (RNA) during screening. NOTE: Cases with unclear interpretation should be discussed with the medical monitor
  9. History of (HIV) infection or a positive test at screening per local requirements

NOTE: Other protocol-defined Inclusion/ Exclusion Criteria apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
288 participants (actual)

Study arms

  • Experimental
    Group 1

    Placebo in DBTP; Re-randomized to Combination or Cemdisiran in ETP. Participants who received combination therapy during ETP and have not yet reached OLTP be reallocated to cemdisiran at the start of OLTP. In OLTP, participants on combination therapy who have not reached week 108 will switch to cemdisiran, while those who have reached week 108 will continue combination therapy

    Drug: Pozelimab + Cemdisiran · Drug: Cemdisiran · Other: Placebo

  • Experimental
    Group 2

    Combination regimen in DBTP and ETP. Participants who have not yet reached OLTP will be reallocated to cemdisiran at the start of OLTP. Participants who are in OLTP and have not reached week 108 will switch to cemdisiran, while those who have reached week 108 will continue combination therapy.

    Drug: Pozelimab + Cemdisiran · Drug: Cemdisiran

  • Experimental
    Group 3

    Cemdisiran throughout the study

    Drug: Cemdisiran

  • Experimental
    Group 4

    Pozelimab monotherapy in DBTP followed by combination in ETP. Participants who have not yet reached OLTP will be reallocated to cemdisiran at the start of OLTP. Participants who are in OLTP and have not reached week 108 will switch to cemdisiran, while those who have reached week 108 will continue combination therapy.

    Drug: Pozelimab + Cemdisiran · Drug: Cemdisiran · Drug: Pozelimab

Interventions

  • DrugPozelimab + Cemdisiran

    Drug pages: Pozelimab · Cemdisiran

    Subcutaneous administration as described in the protocol

  • SC administration as described in the protocol

    Also known as: ALN-CC5

  • OtherPlacebo

    SC administration as described in the protocol

  • SC administration as described in the protocol

    Also known as: REGN3918

06

What researchers measure

Primary outcomes

  1. Change in Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score

    The total MG-ADL score ranges from 0 to 24 points, with higher scores indicating greater functional impairment and disability

    Time frame: From baseline to week 24

Secondary outcomes

  1. Change from baseline in Quantitative Myasthenia Gravis (QMG) score

    QMG total scores range from 0 to 39, with higher scores representing greater impairment

    Time frame: Week 24

  2. Achievement of a ≥3-point reduction (improvement) in MG-ADL total score

    Time frame: From baseline to week 24

  3. Achievement of a ≥5-point reduction (improvement) in QMG total score

    Time frame: From baseline to week 24

  4. Achievement of a consistent response on the MG-ADL

    A participant with a ≥2-point reduction (improvement) in MG-ADL total score on 2 or more consecutive assessments spanning 4 or more weeks during the DBTP

    Time frame: From baseline to week 24

  5. Achievement of Minimal Symptom Expression (MSE)

    Score of 0 to 1 on the MG-ADL

    Time frame: Week 24

  6. Change from baseline in the Myasthenia Gravis Composite (MGC) total score

    MGC score ranges from 0 to 50, with higher score indicating higher impairment

    Time frame: Week 24

  7. Change from baseline in Myasthenia Gravis Quality of Life (MG-QOL15r) total score

    Total score ranges from 0 to 30 points; a higher score represents greater impairment

    Time frame: Week 24

  8. Achievement of a ≥2-, 4-, 5-, 6-, 7-, 8-, 9-, or 10-point reduction on MG-ADL total score

    Time frame: From baseline to week 24

  9. Achievement of a ≥3-, 4-, 6-, 7-, 8-, 9-, or 10-point reduction on QMG

    Time frame: From baseline to week 24

  10. Incidence and severity of Treatment-Emergent Adverse Events (TEAEs) in participants treated with pozelimab + cemdisiran combination therapy, cemdisiran monotherapy or placebo

    Time frame: Through week 24

  11. Incidence and severity of Serious Adverse Events (SAEs) in participants treated with pozelimab + cemdisiran combination therapy, cemdisiran monotherapy or placebo

    Time frame: Through week 24

  12. Incidence and severity of Adverse Events of Special Interest (AESIs) in participants treated with pozelimab + cemdisiran combination therapy, cemdisiran monotherapy or placebo

    Time frame: Through week 24

  13. Concentrations of total pozelimab in serum

    Time frame: Through study duration, approximately 172 weeks

  14. Concentrations of total Complement component 5 (C5) in plasma

    Time frame: Through study duration, approximately 172 weeks

  15. Concentrations of cemdisiran and its metabolites in plasma

    Time frame: Through study duration, approximately 172 weeks

  16. Incidence of treatment-emergent Anti-Drug Antibodies (ADAs) to pozelimab over time

    Time frame: Through study duration, approximately 172 weeks

  17. Incidence of treatment-emergent ADAs to cemdisiran over time

    Time frame: Through study duration, approximately 172 weeks

  18. Change in total complement hemolysis activity assay (CH50) over time

    Time frame: Through study duration, approximately 172 weeks

  19. Percent change in CH50 over time

    Time frame: Through study duration, approximately 172 weeks

  20. Concentrations of cemdisiran and its metabolite in plasma

    During the OLTP for the optional PK sub-study

    Time frame: At week 60 and up to week 120

  21. Concentrations of total C5 in plasma

    During the OLTP for the optional PK sub-study

    Time frame: At week 60 and up to week 120

  22. Incidence of TEAEs

    During the OLTP for the optional PK sub-study

    Time frame: Through week 144

  23. Severity of TEAEs

    During the OLTP for the optional PK sub-study

    Time frame: Through week 144

  24. Incidence of SAEs

    During the OLTP for the optional PK sub-study

    Time frame: Through week 144

  25. Severity of SAEs

    During the OLTP for the optional PK sub-study

    Time frame: Through week 144

  26. Incidence of AESIs

    During the OLTP for the optional PK sub-study

    Time frame: Through week 144

  27. Severity of AESIs

    During the OLTP for the optional PK sub-study

    Time frame: Through week 144

07

Study locations

116 sites

Showing the first 100 of 116 sites across 19 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Vu T, Habib AA, Jacob S, Mantegazza R, Murai H, Vissing J, Shaibani A, Levine T, Hussain Y, Meisel A, Adamczak-Ratajczak A, Ilkowski J, Sgobbi P, Guerreiro A, Luo S, Pavani R, Chaudhari U, Jalali N, DeVeaux M, Moore W, Meagher KA, Burczynski ME, Kokate S, Sherman S, Pawaskar D, Singh N, Souttou A, Sirulnik A, Perlee L, Yancopoulos GD, Howard JF Jr; NIMBLE Trial Investigators. Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2026 May 2;407(10540):1712-1725. doi: 10.1016/S0140-6736(26)00690-2. Epub 2026 Apr 21. PubMed 42030965 ↗

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), the legal authority to share the data, and ensured the ability to protect participant privacy.

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Jul 2025, 42 months.

Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 42 months is above that.

Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2021
First posted
Oct 7, 2021
StartActual
Dec 14, 2021
Primary completionActual
Jul 8, 2025
CompletionEst.
Nov 11, 2028
Results delay requested
Jul 1, 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Seth G.S. Medical College & K.E.M. Hospital, Mumbai · Parel, India
Show 1 removed
  • Seth G.S. Medical College & K.E.M. Hospital, Mumbai · Pārel, India
Oct 28, 2026
Eligibility
1 criterion edited, 1 added
What changed in the criteria
  • AddedFor the optional PK sub-study: Must have a Body Mass Index (BMI) ≥ 18.5 kg/m\^2 and ≤ 30 kg/m\^2 at screening
  • EditedPatientsParticipants with antibody profile that is only positive for Muscle-Specific tyrosine Kinase (MuSK) (MuSK positivity is based on a documented prior history of positive serologic test for antibodies to MuSK or a positive result during screening
Oct 28, 2026
Secondary outcomes
3 edited, 4 time frame changed, 8 added
What changed in the outcomes
  • EditedIncidence and severity of Treatment-Emergent Adverse Events (TEAEs) in participants treated with pozelimab + cemdisiran combination therapy, cemdisiran monotherapy or placeboTime frame: Through week 24
  • EditedIncidence and severity of Serious Adverse Events (SAEs) in participants treated with pozelimab + cemdisiran combination therapy, cemdisiran monotherapy or placeboTime frame: Through week 24
  • EditedIncidence and severity of Adverse Events of Special Interest (AESIs) in participants treated with pozelimab + cemdisiran combination therapy, cemdisiran monotherapy or placeboTime frame: Through week 24
  • AddedConcentrations of cemdisiran and its metabolite in plasmaTime frame: At week 60 and up to week 120
  • AddedConcentrations of total C5 in plasmaTime frame: At week 60 and up to week 120
  • AddedIncidence of TEAEsTime frame: Through week 144
  • AddedSeverity of TEAEsTime frame: Through week 144
  • AddedIncidence of SAEsTime frame: Through week 144
  • AddedSeverity of SAEsTime frame: Through week 144
  • AddedIncidence of AESIsTime frame: Through week 144
  • AddedSeverity of AESIsTime frame: Through week 144
  • Time frameConcentrations of total pozelimab in serumThrough study duration, approximate 172 weeks → Through study duration, approximately 172 weeks
  • Time frameConcentrations of total Complement component 5 (C5) in plasmaThrough study duration, approximate 172 weeks → Through study duration, approximately 172 weeks
  • Time frameConcentrations of cemdisiran and its metabolites in plasmaThrough study duration, approximate 172 weeks → Through study duration, approximately 172 weeks
  • Time frameIncidence of treatment-emergent ADAs to cemdisiran over timeThrough study duration, approximate 172 weeks → Through study duration, approximately 172 weeks
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    1 site added, 1 site removed
    Show site
    • Seth G.S. Medical College & K.E.M. Hospital, Mumbai · Parel, India
    Show 1 removed
    • Seth G.S. Medical College & K.E.M. Hospital, Mumbai · Pārel, India
    Eligibility 1 criterion edited, 1 added
    What changed in the criteria
    • AddedFor the optional PK sub-study: Must have a Body Mass Index (BMI) ≥ 18.5 kg/m\^2 and ≤ 30 kg/m\^2 at screening
    • EditedPatientsParticipants with antibody profile that is only positive for Muscle-Specific tyrosine Kinase (MuSK) (MuSK positivity is based on a documented prior history of positive serologic test for antibodies to MuSK or a positive result during screening
    Secondary outcomes 3 edited, 4 time frame changed, 8 added
    What changed in the outcomes
    • EditedIncidence and severity of Treatment-Emergent Adverse Events (TEAEs) in participants treated with pozelimab + cemdisiran combination therapy, cemdisiran monotherapy or placeboTime frame: Through week 24
    • EditedIncidence and severity of Serious Adverse Events (SAEs) in participants treated with pozelimab + cemdisiran combination therapy, cemdisiran monotherapy or placeboTime frame: Through week 24
    • EditedIncidence and severity of Adverse Events of Special Interest (AESIs) in participants treated with pozelimab + cemdisiran combination therapy, cemdisiran monotherapy or placeboTime frame: Through week 24
    • AddedConcentrations of cemdisiran and its metabolite in plasmaTime frame: At week 60 and up to week 120
    • AddedConcentrations of total C5 in plasmaTime frame: At week 60 and up to week 120
    • AddedIncidence of TEAEsTime frame: Through week 144
    • AddedSeverity of TEAEsTime frame: Through week 144
    • AddedIncidence of SAEsTime frame: Through week 144
    • AddedSeverity of SAEsTime frame: Through week 144
    • AddedIncidence of AESIsTime frame: Through week 144
    • AddedSeverity of AESIsTime frame: Through week 144
    • Time frameConcentrations of total pozelimab in serumThrough study duration, approximate 172 weeks → Through study duration, approximately 172 weeks
    • Time frameConcentrations of total Complement component 5 (C5) in plasmaThrough study duration, approximate 172 weeks → Through study duration, approximately 172 weeks
    • Time frameConcentrations of cemdisiran and its metabolites in plasmaThrough study duration, approximate 172 weeks → Through study duration, approximately 172 weeks
    • Time frameIncidence of treatment-emergent ADAs to cemdisiran over timeThrough study duration, approximate 172 weeks → Through study duration, approximately 172 weeks
    + 3 other changes: identifiers, verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05070858
Responsible party
Sponsor
First posted
Oct 7, 2021
Start date
Dec 14, 2021
Primary completion
Jul 8, 2025
Completion
Nov 11, 2028 (estimated)
Last update
Oct 28, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pozelimab · Cemdisiran

Start the discussion